CD56-positive small round cell tumor: Osseous plasmacytoma manifested in osteolytic tumors of the iliac bone and femora

Japanese Journal of Clinical Oncology

Volumn 35, Issue 2, 2005, Pages 90-93

  Kouno, Tsutomu ^a   Watanabe, Takashi ^a   Umeda, Toru ^a   Beppu, Yasuo ^a   Kojima, Rie ^a   Sungwon, Kim ^a   Kobayashi, Yukio ^a   Tobinai, Kensei ^a   Hasegawa, Tadashi ^a   Matsuno, Yoshihiro ^a  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

Author keywords

CD56; Osseous plasmacytoma; Osteolytic bone tumor; Plasmacytoma; SBP

Indexed keywords

CD56 ANTIGEN; CYCLOPHOSPHAMIDE; DOXORUBICIN; IMMUNOGLOBULIN KAPPA CHAIN; MORPHINE; PREDNISOLONE; VINCRISTINE;

ADULT; ANTIGEN EXPRESSION; ARTHRALGIA; ARTICLE; BONE RESECTION; BONE TUMOR; CANCER INFILTRATION; CANCER INVASION; CASE REPORT; CELL INFILTRATION; CYTOPLASM; DIAGNOSTIC TEST; ELECTRON MICROSCOPY; FEMALE; FEMUR TUMOR; HUMAN; HUMAN CELL; HUMAN TISSUE; ILIAC BONE; IMMUNOPATHOLOGY; OSTEOLYSIS; PLASMA CELL; PLASMACYTOMA; SMALL CELL CARCINOMA; STERNUM; TUMOR CELL; BIOSYNTHESIS; FEMUR; IMMUNOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY;

ADULT; ANTIGENS, CD56; BONE NEOPLASMS; FEMALE; FEMUR; HUMANS; ILIUM; MAGNETIC RESONANCE IMAGING; PLASMACYTOMA;

EID: 15044360024     PISSN: 03682811     EISSN: None     Source Type: Journal    
DOI: 10.1093/jjco/hyi026     Document Type: Article

References (13)

1. Jaffe ES, Harris NL, Stein H, Vardiman JW. World Health Organization Classification of Tumours: Pathology and Genetics, Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: International Agency for Reseach on Cancer Press 2001.
2. Dimopoulos MA, Moulopoulos LA, Maniatis A, Alexanian R. Solitary plasmacytoma of bone and asymptomatic multiple myeloma. Blood 2000;96:2037-44.
3. Van Camp B, Durie BG, Spier C, et al. Plasma cells in multiple myeloma express a natural killer cell-associated antigen: CD56 (NKH-1; Leu-19). Blood 1990;76:377-82.
4. Harada H, Kawano MM, Huang N, et al. Phenotypic difference of normal plasma cells from mature myeloma cells. Blood 1993;81:2658-63.
5. Pellat-Deceunynck C, Barille S, Jego G, et al. The absence of CD56 (NCAM) on malignant plasma cells is a hallmark of plasma cell leukemia and of a special subset of multiple myeloma. Leukemia 1998;12:1977-82.
6. Dahl IM, Rasmussen T, Kauric G, Husebekk A. Differential expression of CD56 and CD44 in the evolution of extramedullary myeloma. Br J Haematol 2002;116:273-7.
7. Sahara N, Takeshita A, Shigeno K, et al. Clinicopathological and prognostic characteristics of CD56-negative multiple myeloma. Br J Haematol 2002;117:882-5.
8. Durie BG. Staging and kinetics of multiple myeloma. Semin Oncol 1986;13:300-9.
9. Suzuki R, Kagami Y, Takeuchi K, et al. Prognostic significance of CD56 expression for ALK-positive and ALK-negative anaplastic large-cell lymphoma of T/null cell phenotype. Blood 2000;96:2993-3000.
10. Jaffe ES, Chan JK, Su IJ, et al. Report of the Workshop on Nasal and Related Extranodal Angiocentric T/Natural Killer Cell Lymphomas. Definitions, differential diagnosis, and epidemiology. Am J Surg Pathol 1996;20:103-11.
11. Okada K, Hasegawa T, Yokoyama R, Beppu Y, Itoi E. Prognostic relevance of rosette-like features in osteosarcoma. J Clin Pathol 2003;56:831-4.
12. Walsh FS, Doherty P. Neural cell adhesion molecules of the immunoglobulin superfamily: role in axon growth and guidance. Annu Rev Cell Dev Biol 1997;13:425-56.
13. Ely SA, Knowles DM. Expression of CD56/neural cell adhesion molecule correlates with the presence of lytic bone lesions in multiple myeloma and distinguishes myeloma from monoclonal gammopathy of undetermined significance and lymphomas with plasmacytoid differentiation. Am J Pathol 2002;160:1293-99.